The STAR Market was a major reform measure of the national capital market，independent of the existing main board and the GEM. A pilot program of a long-established national registration system was carried out in this sector. In early March，2019，the chairman of the China Securities Regulatory Commission，Yi Huiman，signed Decree No.153 and Decree No.154 and officially issued six major business rules. This report introduced the main listing standards and rapid advancement of the STAR Market，and analyzed the significant opportunities that the STAR Market brought to the listing，investment and innovation of pharmaceutical companies.